MAT2A

Across TCGA pan-cancer cohorts, MAT2A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAT2A data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAT2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAT2A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where MAT2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.970	0.768	.002	36	view →
PDAC	OS	Tertile	IV	0.455	0.836	.024	6	view →
GBM	DFS	Median	All	0.773	0.588	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAT2A–CCRCC (DFS)

Open the CCRCC breakdown →